Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (19012)	4/1/2004 3:24:28 PM
From: Paul Senior	Read Replies (3) \| Respond to of 78527

Nrgn: low hanging fruit for you Madharry, but fruit not easily seen by me. If I could get the $9.22 stock under $7, which is what the $100M in equity was paid in the private placement, I might be interested. I'm guessing there's no profits to be forthcoming in the next year, so I further speculate that the stock price could fluctuate as drug discovery and development companies prices seem to me to do. So I might get a chance at NRGN at a below $7 price. Jmo after a quick look. Paul Senior (Not saying the stock couldn't or won't retest or surpass annual high, only that I can't make out the value proposition for it.)